• Citius Oncology received Nasdaq's extension notice October 19, 2026, setting April 19, 2027, as its $1 minimum bid-price compliance deadline.
• Compliance requires the common stock's closing bid price to reach at least $1 for a minimum of 10 consecutive business days.
• Failure to regain compliance by the deadline would trigger a delisting notice; the company may appeal to a Nasdaq hearings panel.
• The extension leaves the common stock trading on the Nasdaq Capital Market under CTOR while the company evaluates compliance options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-112109), on October 23, 2026, and is solely responsible for the information contained therein.